Vanguard Group Inc. Cuts Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Vanguard Group Inc. decreased its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 11.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 19,538,555 shares of the biotechnology company’s stock after selling 2,499,542 shares during the period. Vanguard Group Inc. owned about 0.12% of Ironwood Pharmaceuticals worth $86,556,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. State Street Corp boosted its stake in shares of Ironwood Pharmaceuticals by 7.3% during the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock valued at $40,870,000 after acquiring an additional 677,024 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock valued at $51,967,000 after acquiring an additional 450,949 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Ironwood Pharmaceuticals by 23.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock valued at $7,846,000 after purchasing an additional 364,841 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in Ironwood Pharmaceuticals by 2,625.1% during the fourth quarter. Los Angeles Capital Management LLC now owns 331,700 shares of the biotechnology company’s stock worth $1,469,000 after buying an additional 319,528 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in Ironwood Pharmaceuticals by 170.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 341,455 shares of the biotechnology company’s stock valued at $1,513,000 after purchasing an additional 215,166 shares in the last quarter.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the transaction, the chief executive officer now directly owns 1,160,634 shares in the company, valued at $2,042,715.84. This trade represents a 10.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the transaction, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. The trade was a 6.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 192,381 shares of company stock worth $338,591. Corporate insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Stock Down 7.2 %

Shares of NASDAQ IRWD opened at $1.03 on Thursday. The stock has a market cap of $166.66 million, a P/E ratio of -34.33 and a beta of 0.30. The firm’s 50-day simple moving average is $1.60 and its 200 day simple moving average is $3.17. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $0.91 and a fifty-two week high of $8.45.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm had revenue of $90.55 million during the quarter, compared to the consensus estimate of $93.85 million. On average, sell-side analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on IRWD shares. Craig Hallum dropped their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 29th. Finally, JMP Securities cut their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Ironwood Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.60.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.